Allogene Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
ALLO$1.06+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $51,688 | $75,218 |
| Short-term investments | 198,522 | 217,258 |
| Prepaid expenses and other current assets | 7,539 | 10,910 |
| Total current assets | 257,749 | 303,386 |
| Long-term investments | 8,043 | 80,673 |
| Operating lease right-of-use asset | 39,888 | 45,205 |
| Property and equipment, net | 72,839 | 86,056 |
| Deposit placed in escrow | 23,479 | 20,773 |
| Restricted cash | 10,292 | 10,292 |
| Other long-term assets | 3,615 | 2,325 |
| Total assets | $415,905 | $548,710 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,270 | $5,394 |
| Accrued and other current liabilities | 28,244 | 30,129 |
| Total current liabilities | 32,514 | 35,523 |
| Lease liability, noncurrent | 75,045 | 83,247 |
| Other long-term liabilities | 15,804 | 7,761 |
| Total liabilities | 123,363 | 126,531 |
| Commitments and Contingencies (Notes 6 and 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value: 10,000,000 authorized as of December 31, 2025 and December 31, 2024; no shares were issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value: 400,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 229,413,523 and 212,210,597 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 229 | 212 |
| Additional paid-in capital | 2,302,753 | 2,241,879 |
| Accumulated deficit | (2,010,709) | (1,819,823) |
| Accumulated other comprehensive gain (loss) | 269 | (89) |
| Total stockholders’ equity | 292,542 | 422,179 |
| Total liabilities and stockholders’ equity | $415,905 | $548,710 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.